Cetuximab-induced cutaneous toxicity

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 6, 2010, Pages 692-696

  Tomkova H ^a   Kohoutek, M ^a   Zabojnikova M ^a   Pospiskova M ^a   Ostrizkova L ^a   Gharibyar, M ^a  

^a T Bata's Regional Hospital   (Czech Republic)

Author keywords

Acneiform eruptions; Anaphylaxis; Cetuximab; Drug toxicity; Epidermal growth factor receptor; Radiodermatitis

Indexed keywords

CETUXIMAB; CHLORAMPHENICOL; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; METRONIDAZOLE; SALICYLIC ACID; ZINC; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACNE; ADULT; AGED; ANAPHYLAXIS; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CANCER; HUMAN; MACULOPAPULAR RASH; MALE; PARONYCHIA; PATIENT REFERRAL; PRIORITY JOURNAL; PUSTULE; RADIATION DERMATITIS; SKIN TOXICITY; XEROSIS; ACNEIFORM ERUPTIONS; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; HEAD AND NECK NEOPLASMS; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ACNEIFORM ERUPTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952137431     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03490.x     Document Type: Article

References (21)

1. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000 10 : 505 510.
2. Nanney LB, Stoscheck CM, King LE Jr. et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990 94 : 742 748.
3. Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park) 2006 20 (suppl 2 26 34.
4. Van Cutsem E, Mayer RJ, Gold P et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer Suppl 2004 2 : 85.
5. Orditura M, De Vita F, Galizia G et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009 21 : 1023 1028.
6. Hu JC, Sadeghi P, Pinter-Brown LC et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007 56 : 317 326.
7. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005 6 : 491 500.
8. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005 16 : 1425 1433.
9. Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008 19 : 142 149.
10. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008 58 : 545 570.
11. Erbitux. Summary of product characteristics 2006 http://www.emea.europa. eu/humandocs/PDFs/EPAR/erbitux/H-558-Pl-en.pdf
12. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997 109 : 751 756.
13. Woodworth CD, Michael E, Marker D et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005 4 : 650 658.
14. Lynch TJ Jr., Kim ES, Eaby B et al. Pathobiology of EGFRI-associated cutaneous toxicities. Oncologist 2007 12 : 610 621.
15. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001 144 : 1169 1176.
16. Mitsui S, Ohuchi A, Adachi-Yamada T et al. Cyclin-dependent kinase inhibitors, p21(waf1/cip1) and p27(kip1), are expressed site- and hair cycle-dependently in rat hair follicles. J Dermatol Sci 2001 25 : 164 169.
17. De Noronha e Menezes NMBV, Lima R, Moreira A et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 2009 19 : 248 251.
18. Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruptions. J Clin Oncol 2007 25 : 5390 5396.
19. ERBITUX (cetuximab) [package insert].
20. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008 13 : 725 732.
21. Common Terminology Criteria for Adverse Events v4.0 (CTCAE) http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev4. pdf